Webster purchases top quality customer and healthcare services companies with EBITDAs from $3 million to $15 million and transaction worths from $15 million to $200 million. In August 2018, the company held an oversubscribed and last closing of Webster Capital IV LP at its difficult cap of $875 million. Webster was established in 2003 and is based in the Boston suburban area of Waltham, Massachusetts.
” Belmar Pharmacy values our collaborations with our customers and the neighborhoods we serve,” said Jaime Rios, president of APS Pharmacy. “We picked to merge with Belmar Pharmacies so that we can continue to fulfill the growing demands of our market, and possibly expand the services we provide to those in need. Belmars worths, standards and quality of service reflect those of APS Pharmacy, making this merger a natural fit.”
Belmar Drug store, a compounding drug store and a portfolio business of Webster Equity Partners and MedEquity Capital, has acquired APS Pharmacy.
Belmar runs both 503A and 503B compounding facilities. 503A centers are traditional compounding drug stores that produce a product in accordance with patient-specific prescriptions and are required by the state boards of drug store to abide by the USP (United States Pharmacopeia) and its guidelines. On the other hand, 503B facilities produce big batches of products, with or without prescriptions, that are sold to health care facilities.
Belmar, gotten by Webster and MedEquity in May 2019, services more than 6,500 providers and more than 64,000 clients each year throughout 46 states. The business, led by CEO Dave Hill, was founded in 1985 and is headquartered in Golden, Colorado.
” APS company is extremely complementary to ours,” said Belmar CEO Dave Hill. “At Belmar– through the 503A compounding drug store and 503B pellet manufacturing company– we can offer patients with “strong dosage form” hormone replacement treatment (HRT). APS mostly concentrates on the “sterile injectable” aspect of HRT– this merger will assist us broaden our item providing to service all of our consumers needs.”
MedEquity Capital, which has actually co-invested with Webster prior to, buys health care services, distribution and products companies that have incomes of $1.5 million to $20 million and EBITDA of $0.5 million to $4 million. MedEquity is based west of Boston in Wellesley Hills, Massachusetts.
APS Pharmacy provides pharmaceutical compounding to clients and doctors across the country throughout 48 states. The business focuses mainly on hormone replacement treatment (injectable testosterone); as well as compounds for autism, opioid addiction, intravenous nutritionals, nootropics (compounds that boost mental abilities); allergies; and impotence. APS, a 503A pharmacy, was established in 2005 and is headquartered in Palm Harbor, Florida.
Intensifying pharmacies integrate, mix, or change several active ingredients to develop a medication that is customized to the needs of a specific patient.
Private Equity Professional|July 1, 2020
intensifying drug store
503A centers are traditional intensifying pharmacies that produce a product in accordance with patient-specific prescriptions and are needed by the state boards of drug store to comply with the USP (United States Pharmacopeia) and its guidelines. “At Belmar– through the 503A intensifying pharmacy and 503B pellet manufacturing company– we can offer clients with “solid dosage kind” hormone replacement treatment (HRT).” Belmar Pharmacy values our partnerships with our customers and the neighborhoods we serve,” stated Jaime Rios, president of APS Pharmacy. Belmars worths, requirements and quality of service reflect those of APS Pharmacy, making this merger a natural fit.”